Cizzle Biotechnology research and development agreement with St George Street Capital

Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced it has executed a research and development agreement to develop a companion diagnostic test for autoimmune disease with St George Street Capital, the UK-based biomedical charity.  The new diagnostic platform will be used to develop tests that will operate alongside SGSC’s programme for the development of therapeutic assets licensed to SGSC from one of the world’s largest pharmaceutical companies, Astra Zeneca.  This seeks to address unmet clinical needs in a wide variety of autoimmune diseases which will significantly broaden the Company’s product pipeline and for which SGSC will pay Cizzle Biotechnology up to £1 million in development fees.

As announced on 20 September 2021, Cizzle Biotechnology signed an agreement with SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street’s therapeutic asset AZD1656 of up to £5 million.  This followed SGSC’s announcement on 9 September 2021 of encouraging clinical trial results arising from their existing collaboration with AstraZeneca and funded by international investment through Excalibur Medicines Ltd and an HM Government grant through the UKRI/Innovate UK programme.

This new commercial contract with SGSC will seek to provide valuable diagnostic information on patients based on the proposed mechanism of action of AZD1656 which may be linked to the regulation of inflammation through activating migration of T regulatory cells to sites of damaging inflammation.  Migration of T regulatory cells amplify the body’s own mechanism of damping down an inappropriate inflammatory overreaction and hence may have important clinical benefits in managing autoimmune disease.

Under the commercial contract entered into, the parties will collaborate closely in the design and development of the test and in consideration SGSC will pay Cizzle Biotechnology £200,000 upfront on commencement of the project and then further milestone payments totalling up to £1 million.  A further announcement will be made when the project commences.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: “We announced on 20 September following SGSC’s successful ARCADIA clinical trial, a royalty agreement related to AZD1656.  We are now also delighted to sign a new R&D agreement with SGSC to develop a companion diagnostic which has fees payable to Cizzle Biotechnology of up to £1 million.  This will strengthen the two parties’ close relationship through the development of a companion diagnostic test for the use of their therapeutic asset that is aimed at addressing unmet needs in the area of autoimmune disease.  A potential pipeline of new diagnostic tests for SGSC will significantly broaden Cizzle Biotechnology’s product portfolio as we continue to develop our simple blood test for the early detection of lung cancer based on the C1Z1B biomarker.”

Commenting, Professor John Martin of UCL, Chairman of SGSC, said: “We announced last month the encouraging clinical trial results of our new treatment for COVID-19 and completed our formal royalty sharing agreement with Cizzle Biotechnology.  Today we are pleased to extend that relationship through the signing of a new agreement to collaborate in the development of a companion diagnostic for use with our therapeutic asset AZD 1656 for autoimmune disease.  We continue to be impressed with the progress of this long-term relationship with Cizzle Biotechnology, which combines unique skills, experience and capabilities from each party to build complimentary diagnostic and therapeutic products of important clinical utility.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology completes evaluation programme with Bio-Techne

    Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of

    Cizzle Biotech

    Cizzle Biotechnology secures transaction with Conduit

    Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat

    Cizzle Biotech

    Cizzle Biotechnology AGM to be held on 27 June 2022

    Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, have been sent to